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Abstract
Comprehensive characterization of the antigen-specific B cells induced during infections or
following vaccination would facilitate the discovery of novel antibodies and inform how
interventions shape protective humoral responses. The analysis of human B cells and their
antibodies has been performed using flow cytometry to evaluate memory B cells and expanded
plasmablasts, while microtechnologies have also provided a useful tool to examine plasmablasts/
plasma cells after vaccination. Here we present an integrated analytical platform using arrays of
subnanoliter wells (nanowells) for constructing detailed profiles for human B cells comprising the
immunophenotypes of the cells, the distribution of isotypes of secreted antibodies, the specificity
and relative affinity for defined antigens, and for a subset of cells, the genes encoding the heavy
and light chains. The approach combines on-chip image cytometry, microengraving, and single-
cell RT-PCR. Using clinical samples from HIV-infected subjects, we demonstrate that the method
can identify antigen-specific neutralizing antibodies, is compatible with both plasmablasts/plasma
cells and activated memory B cells, and is well-suited for characterizing the limited numbers of B
cells isolated from tissue biopsies (e.g., colonic biopsies). The technology should facilitate
detailed analyses of human humoral responses for evaluating vaccines and their ability to raise
protective antibody responses across multiple anatomical compartments.
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1. Introduction
Characterizing the nature and breadth of the antibody responses generated in humans is
important for understanding how vaccines elicit prophylactic protection and for developing
new insights to designing effective vaccines against diseases such as HIV, hepatitis C,
tuberculosis, and malaria. Despite strong correlates of protection associating humoral
responses with common vaccines, it is still unclear how to elicit such responses by rational
design. Strategies for reverse engineering of immunogens for vaccines depend on efficient
means for identifying and characterizing neutralizing antibodies from infected patients [1,
2]. Furthermore, the enumeration of novel antibodies with useful properties (e.g., broad and
potent neutralizing activity) directly from humans may also provide new candidates for
therapies and diagnostics. In this paper, we present a process for evaluating antigen-specific
B cells from humans using a dense array of subnanoliter wells (nanowells) and an integrated
set of analytical operations.
The most developed approaches to identify and recover individual antigen-specific B cells
from primary samples use fluorescence-activated cell sorting (FACS). Sorting of individual
memory B cells labeled with fluorescent antigen bound to surface-expressed
immunoglobulins (Igs) has enabled the discovery of novel antibodies, including new broadly
neutralizing antibodies from HIV-infected subjects [3, 4]. Following acute infection or
vaccination, indiscriminate sorting of plasma cells or plasmablasts has also enabled the
recovery of native human antibodies to pathogens like influenza [5–7]. For chronic diseases
like HIV, however, this approach is relatively inefficient since the antigen-specific cells of
interest represent only a minor fraction of all activated B cells [8]. The ELISPOT-like
immunospot array assay on a chip (ISAAC) has also facilitated the recovery of antigen-
specific antibody-secreting cells (ASCs) from recently vaccinated subjects [9].
We have previously demonstrated the use of arrays of nanowells to recover mouse
hybridomas producing antigen-specific antibodies [10, 11], and to characterize the diversity
of isotypes and affinities among the antigen-specific antibodies produced by primary mouse
B cells following immunization [12]. Here we present a new integrated analytical process
that extends these approaches to efficiently and comprehensively evaluate human B cells.
The process combines image-based cytometry, microengraving, and automated
micromanipulation to yield multidimensional data on the immunophenotypes of the B cells,
the distribution of isotypes of secreted antibodies and the relative affinity of the secreted
antibodies for specific antigens for thousands of cells in parallel. In addition, for antigen-
specific antibodies, the method allows the recovery of the paired genes encoding the
variable regions of the heavy and light chains. We show that the approach can be applied to
characterize ASCs and activated memory B cells from the same individual, as well as B
cells isolated from mucosal tissue biopsies. The flexibility and compatibility of the
technique with small samples makes this approach a useful complement to existing methods
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for evaluating humoral responses in humans, and should provide a rapid and cost-effective
technology for monitoring responses to vaccines and pathogens across different
compartments.
2. Materials and methods
A detailed description of methods used is included as supplementary information in
Appendix.
2.1. Ethics statement
Patient samples were obtained following approval by the institutional review boards at
Massachusetts General Hospital (MGH), Boston; Massachusetts Institute of Technology
(MIT), Cambridge; and Brigham and Women’s Hospital (BWH), Boston. Written informed
consent was obtained from study participants prior to enrollment in the study.
2.2. Peripheral blood and mucosal tissue samples
Blood and intestinal biopsies were collected from HIV-infected individuals from a cohort of
controllers (HIV viral load <2,000 RNA copies/ml in the absence of ART) from MGH [13].
PBMCs from blood samples were isolated using Histopaque®-1077 (Sigma-Aldrich). Cells
were then either analyzed fresh or from frozen aliquots of 107 cells. Intestinal biopsies were
obtained by upper and lower endoscopy. Tissue was disaggregated using both mechanical
disruption and enzymatic digestion, based on published protocols [14]. Recovered mucosal
cells were washed in media and used fresh. PBMCs from healthy donors were obtained from
BWH or purchased from SeraCare Life Sciences Inc. (Milford, MA). Before screening
populations of ASCs, PBMCs were thawed and rested for 1 h in complete media (RPMI
1640 media supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin
and 100 μg/mL streptomycin; 37°C, 5% CO2).
2.3 Activation of memory B cells
A mixture of stimulatory molecules based on a previous report for polyclonal activation of B
cells [15] was used to induce antibody secretion by resting memory B cells. ~3 × 106
PBMCs were seeded in 5 mL round-bottom tubes (BD Falcon) and incubated for 3–7 days
in 500 μL of complete media, containing CD40L (2.5 μg/mL, Peprotech), IL-21 (50 ng/mL,
eBioscience), anti-human APO1 (2.5 μg/mL, eBioscience) and EBV (5 μg, Advanced
Biotechnology Inc.).
2.4. Antibody-producing cell lines
Chinese hamster ovary (CHO) cell lines producing b12 (anti-gp120) and 2F5 (anti-gp41)
antibodies (courtesy of D. Burton, Scripps Institute) were cultured in ProCHO-5 media
(Lonza) with 3% FBS, 1× HT supplement (Gibco), 1× GS supplement (Sigma-Aldrich), 100
U/mL penicillin, 100 μg/mL streptomycin and 50 μM L-methionine sulfoxime (Sigma-
Aldrich). A human B cell hybridoma cell line producing the 4D20 (anti-hemagglutinin)
antibody [16] (courtesy of J. Crowe, Vanderbilt University) was adapted to grow in RPMI
1640 media with 15% (v/v) FBS, 2 mM L-glutamine and 1 mM sodium pyruvate. Cultures
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were passaged every 3–5 days and used in experiments when cultures were 70–80%
confluent.
2.5. Fabrication of arrays of nanowells
Arrays with ~80,000–250,000 wells (50 × 50 × 50 μm3 or 30 × 30 × 30 μm3 in dimension,
respectively) were manufactured as previously described using poly (dimethylsiloxane)
(Sylgard 184) [11, 17]. After curing in custom-made injection molds, arrays were removed,
covered and stored at ambient conditions until use. Arrays were treated with oxygen plasma
(PDC-001, Harrick Plasma) immediately prior to use.
2.6. Image-based cytometry
PBMCs were stained for viability and surface-expressed proteins with CellTrace™ Calcein
Violet AM and a panel of mouse anti-human antibodies – anti-CD19 (clone SJ25-C1, Qdot®
605 conjugate), anti-CD20 (clone 2H7, Alexa Fluor® 488 conjugate), anti-CD38 (clone
HB7, PerCP-eFluor® 710 conjugate), and anti-CD138 (clone B-B4, APC conjugate), using
manufacturers’ recommended concentrations. Cells were labeled for 30 min at room
temperature in complete media. After staining, cells were deposited onto an array of
nanowells to obtain a density of ~3–5 cells/well, washed with PBS containing 2% (v/v)
FBS, and covered with a LifterSlip™ (EMS). Given that these cells constitute only ~5% of
total PBMCs, each occupied well at this density holds 1 B cell on average. Transmitted-light
and fluorescent images were then acquired on an automated epifluoresence microscope (Carl
Zeiss) fit with an EM-CCD camera (Hamamatsu). The images were analyzed on a block-by-
block basis using custom software [18] to determine the viability and the level of expression
for each marker. Data were gated first for size then mean fluorescence intensities were
extracted for the different fluorescent channels.
2.7. Microengraving
A protocol outlining this technique has been published [11]. For evaluating human B cells,
poly-L-lysine-functionalized glass slides were coated with a polyclonal donkey anti-human
(H+L) antibody (25 μg/mL, Jackson Immunoresearch), and microengraving was conducted
for 2 h. Microarrays were scanned on a GenePix® 4200AL and analyzed with GenePix® Pro
6.0 (Molecular Devices). Printed elements in the arrays were considered Ig+ with %
saturation ≤ 2, signal-to-noise ratio ≥ 1, ≥ 40% of pixels above background + 1 standard
deviation and CV ≤ 200, and after compensation for bleed-through of signal from adjacent
channels. All antigen-specific events were also confirmed by visual inspection since they
were typically <10% of all Ig+ events.
2.8. Variable gene recovery and amplification
Cells were retrieved with an automated micromanipulator (AVISO CellCelector™, ALS
GmbH) [19], and deposited into 20 μL 1× First-Strand Buffer (Invitrogen) and 10 U
RNasin® (Promega) in the wells of a 96-well PCR plate. Heavy and light chain variable
genes were amplified using primer sets and protocols previously described with
modifications [20, 21]. Germline V(D)J usage and CDR3 sequences were determined using
IMGT [22].
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2.9. Antibody expression and validation
Paired heavy and light chain genes were cloned into vectors for expression as human IgG1
(courtesy of M. Nussenzweig, Rockefeller University), based on a published protocol [23].
Cloned antibodies were transiently expressed in human embryonic kidney (HEK) 293T cells
(ATCC). Despite successful recovery and sequencing, we note that ~30% of antibodies
selected did not clone or express as full-length human IgG1 after transfection in the host cell
line, especially with antibodies from non-IgG1 isotypes (Table A1, Appendix). Antibodies
in culture supernatants were assayed for binding on a custom protein microarray comprising
a cross-clade panel of recombinant HIV envelope (Env) proteins (Table A2, Appendix).
Microarrays were scanned on GenePix® 4200AL and analyzed with GenePix® Pro 6.0.
2.10. Neutralization assay
Neutralizing activity of expressed antibodies was tested using a published neutralization
assay [24].
3. Results
3.1. Nanowell-based analysis of human antibody-secreting cells
We designed a new analytical process that combines microengraving, epifluoresence
microscopy and single-cell RT-PCR to comprehensively characterize primary human B cells
involved in antigen-specific responses (Fig. 1). Cells were used either directly or after
activation with stimulants – depending on the subset analyzed – and then stained for
viability and surface receptors. The labeled cells were deposited into arrays of 84,672
nanowells, to allow the analysis of ~100,000 total cells per array. The arrays were imaged on
an epifluoresence microscope to record the expressed phenotypes of every cell and the
occupancy of each well. Microengraving was then performed to capture secreted antibodies.
The antibody microarrays produced were incubated with solution-phase antigens and then
with labeled detection antibodies to highlight antigen-specific antibodies. Cells of interest
were recovered with an automated micromanipulator (~60 cells/h), and heavy and light
chain variable genes amplified by RT-PCR then sequenced. The efficiency of amplifying
genes from cells recovered after microengraving ranged from 30–70%. This combined
approach typically yields data for ~103–104 Ig-secreting cells per array and can be
completed in 3–4 days.
3.2. On-chip cytometry for immunophenotyping of human B cells
The evolution of B cells from plasmablasts to terminally differentiated plasma cells is
accompanied by the increased expression and/or downregulation of CD19, CD20, CD38 and
CD138 cell-surface receptors [25]. We validated a panel of detection antibodies against
these receptors for analysis of B cells in nanowells by image-based cytometry (Fig. 2A). The
distributions of populations enumerated on-chip were similar to those determined by flow
cytometry (Fig. 2B). These results indicate that image-based cytometry can sufficiently
resolve the major classes of B cells, despite the narrower dynamic range typically available
on epifluoresence microscopes equipped with CCDs.
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3.3. Microengraving for the classification of isotypes and antigen-specific antibodies
Microengraving is a soft-lithographic technique that allows the capture and analysis of
molecules secreted by cells confined in an array of nanowells [10]. To establish the utility of
this method for characterizing the antibodies secreted from human B cells, we used cells
isolated from HIV-infected subjects. This choice of sample allowed us to test and optimize
different configurations of the assay, and to compare our results to well-characterized
antibodies (e.g., b12, 2G12, 2F5, VRC01). To analyze the distribution of isotypes of
antibodies secreted, we validated a panel of antibodies to detect secreted IgG1, IgA1/2,
IgG3, and IgM, as well as specificity for an HIV-related antigen (Fig 3A). These isotypes
were chosen based on their prevalence and importance in mediating B cell effector
functions. We verified with hand-spotted microarrays [11] that >10 ng/ml of each isotype
can be detected in supernatants—a concentration much less than that estimated to result
during microengraving for 2 h with ASCs (~10 μg/mL) [26].
One advantage of microengraving is the flexibility to interrogate the resulting antibody
microarrays with different probes to highlight specificities for different antigens. We found
that microengraving could identify Env-specific antibodies using a range of probes derived
from Env proteins. The probes tested included recombinant proteins (e.g., gp120, gp140),
peptides (e.g., MPER-derived peptides 179.4 and 57), and inactivated virus-like particles
(BaL microvesicles, MVs; courtesy of J. Lifson, NCI-Frederick). Using cell lines producing
antibodies that bind gp120 (b12), gp41 (2F5) and influenza HA (4D20) as a negative
control, we determined that sensitivities for antigen-specific detection were all high
(monomeric YU2 gp140: 88.4% for b12; BaL MVs: 99.9% for b12; MPER peptides: ≥
99.7% for 2F5) with thresholds set such that specificities were ≥ 95% (Fig. A1, Appendix).
Furthermore, serial dilution of CHO cells producing b12 into populations of cells producing
2F5 allowed us to estimate the lower limit of detection for rare cells in a population to be 1
in 100,000 cells (Fig. 3B). The limit appears to scale linearly with the number of wells/cells
analyzed, and is 1–2 orders of magnitude lower than that typically achieved by flow
cytometry [27, 28]. These results together demonstrate that microengraving can identify rare
cells producing desired antibodies.
3.4. Nanowell-based analysis of primary B cells from HIV-infected subjects
To establish the utility of this nanowell-based approach for examining the human humoral
response, we applied our integrated analytical process to cells from HIV-infected subjects.
In one example, we compared antibodies produced by plasmablasts/plasma cells and
memory B cells circulating in blood from an HIV-infected elite controller (CTR0118). For
both populations of cells, we determined the phenotypes of the viable cells, the isotypes of
the secreted antibodies and their relative affinities for monomeric YU2 gp140 (Fig. 4A).
IgG1 was observed to be the predominant isotype secreted in circulation, as expected [29].
For this subject, no Env-specific events were found in the circulating ASCs, but ~0.5% of
Ig+ events were Env-specific among the memory B cells.
The ability to isolate small numbers of cells using arrays of nanowells makes this process
well-suited to characterize B cells recovered from other anatomical sites such as the colon,
small bowel or reproductive tracts. To demonstrate this aspect of the technology, we
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analyzed mononuclear cells from the blood and colon of another HIV-infected elite
controller (013646A) (Fig 4B). In this example, antibodies captured by microengraving were
assayed for reactivity to BaL MVs. A large fraction of the cells isolated from the colon
produced IgA1/2, as expected [29, 30]. For this subject, the frequency of antigen-specific
events within this isotype was small (≤ 0.14%). Overall, the enumerated frequency of Env-
specific antibodies was higher in the blood (7%) than in the colon (1.2%), with a wide range
of apparent affinities observed.
Cells from the different samples were recovered for subsequent amplification by RT-PCR
and the resulting sequences analyzed (Table 1). The average mutation rate (considering only
mutations in V genes) for heavy chains of Env-specific monoclonals was 6.9% nucleotides
and for light chains, 3.5% nucleotides. CDR3 lengths ranged from 11–25 amino acids for
heavy chains, and from 7–13 amino acids for light chains. Together, the data from these two
elite controllers demonstrate the nanowell-based approach can easily accommodate the
comparative analyses of B cells from different cellular and anatomical compartments.
3.5. Validation of identified antibodies
To confirm the antibodies identified by microengraving are specific, we cloned and
transiently expressed a subset of antibodies recovered in screens of samples from infected
patients. Of 8 Env-reactive antibodies expressed, 3 were identified with BaL MVs, and 5
with monomeric YU2 gp140. Dilutions of the supernatants containing expressed Ig, and a
set of well-characterized antibodies as controls, were applied to protein microarrays
comprising a cross-clade panel of HIV antigens and an anti-Ig capture antibody (for
normalization of the data) (Fig. 5A). Of the supernatants analyzed, only MIT 02 (derived
from IgM) did not bind to any of the proteins. Some of the antibodies exhibited breadth in
binding for a number of gp120 variants across all clades (MIT 44, 45, 64, 65), and another
exhibited preference for gp41 (MIT 78). Similar to b12 and VRC01, two of the antibodies
(MIT 34 and 41) demonstrated selective binding for the wildtype monomeric YU2 gp120,
but not a mutant form (D368R) that has the CD4 binding site abrogated, and thus can
neutralize the virus. We found that these two antibodies did, indeed, exhibit neutralizing
activity (Fig. 6B; Table A3, Appendix). These results demonstrate that microengraving can
identify antigen-specific antibodies from human B cells, and that it is feasible to recover
neutralizing antibodies from HIV-infected subjects.
4. Discussion
We present here an integrated process for generating detailed profiles of human humoral
responses that highlight characteristics of both antigen-specific B cells and their antibodies.
The approach extends the capabilities of the nanowell platform beyond the characterization
of mouse B cells and hybridomas [12], and incorporates the ability to recover the genes
encoding human antibodies of interest by single-cell RT-PCR. The combination of on-chip
cytometry, microengraving, and RT-PCR yields comprehensive data on the
immunophenotypes of B cells, the isotypes and relative affinities of their antibodies for
particular antigens, as well as the genes of the variable regions of the antibodies. We showed
that this approach produces detailed profiles of the diversity of HIV Env-specific B cells
present in blood and mucosal tissue, and yielded new antibodies with neutralizing activity.
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The integrated process for profiling the breadth of antigen-specific human B cells has three
advantages over methods relying on FACS and other microtechnologies. First, the method is
well-suited to characterize primary B cells from any anatomical site from which a biopsy
can be obtained. The example shown here with cells from a colonic biopsy underscores the
ability to isolate and interrogate single cells from samples when the total numbers of cells
are limited (~105 cells). This capability should enable detailed profiling of the cells
contributing to humoral responses at sites of infection and those raised in mucosal tissues
following vaccination. Second, compared to flow cytometry, microengraving has better
sensitivity for rare cells and allows characterization of the specificity of antibodies from
plasmablasts/plasma cells without compulsory recombinant expression. Third, compared to
other microtechnologies demonstrated for antibody screening [9, 31], the ability to separate
secreted antibodies physically from the cells producing them allows for easy multiplexed
characterization and repeated analysis of the antibodies without potential damage or loss of
source cells. Here we have shown that antibody microarrays produced by microengraving
can be probed by inactivated virions, but other modalities of screening that use intact
pathogens (e.g., fungi or bacteria) are also possible (J.C.L., unpublished results),
highlighting the applicability of the method for identifying antibodies of interest in other
disease models.
In conclusion, our technique for the integrated analysis of ASCs and memory B cells from
primary human clinical samples should facilitate the discovery of cells producing antigen-
reactive antibodies against targets such as HIV, or immunogens used in vaccination. The
routine application of this technology in the analysis of tissue and blood samples would
provide, at the single-cell level, a snapshot of the antigen-specific humoral response elicited
following infection or vaccination. The further integration of this technology for direct
enumeration of antigen-specific B cells with next-generation sequencing technologies would
provide a comprehensive view of the B cell repertoire, and improve the understanding and
design of vaccines targeting elusive pathogens like HIV.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Process schematic for the integrated analysis of B cells using microengraving and on-chip
cytometry. Incubation step to activate memory B cells is optional (dashed outline).
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Figure 2.
Comparison of on-chip cytometry and flow cytometry. PBMCs from a healthy donor were
stained for viability with Calcein violet AM, and for expression of CD19, CD20, CD38 and
CD138. A portion of the labeled cells were loaded onto an array of nanowells and imaged by
epifluoresence microscopy. The remaining cells were analyzed on a BD LSRFortessa™ cell
analyzer. (A) Representative micrographs from wells with single cells displaying different
expression patterns. Signals gated as positive with custom-built analysis script are
highlighted with orange boxes for each. (B) Density plots of both flow cytometry (top) and
on-chip cytometry (bottom) generated from the same sample.
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Figure 3.
Concurrent profiling of isotype and antigen-specificity by microengraving. (A) Primary
antibody-secreting cells were analyzed by microengraving, and the resulting microarray was
incubated with solution-phase, fluorescently-labeled recombinant gp140 monomer (YU2
strain), and our optimized panel of anti-human Ig detection antibodies. Representative
micrographs of the different isotypes detected are shown, with signals gated as positive for
IgG1, IgA1/2, IgG3, IgM and bound antigen highlighted. (B) Plot of number of b12-
producing cells enumerated by microengraving as a function of their dilution. Frequencies of
CHO-b12 cells in samples were calculated as the ratio of the number of IgG+MV+ spots
with CHO-b12 cells present in the wells, and the total number of IgG+ events.
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Figure 4.
(A) Integrated analysis of humoral responses from actively secreting cells or memory B cells
in an HIV-infected sample. Bulk mononuclear cells from the blood were profiled for
viability, surface-expressed phenotypes, isotype distribution and specificity of secreted
antibodies for recombinant monomeric gp140 (YU2 strain, 25 μg/mL). Values in Venn
diagrams represent the total numbers of cells on each array of nanowells. Distributions in
pie-charts include events from wells with ≤ 5 live cells (~ 1 B cell/well). Apparent relative
affinities are presented compared to median values observed from binding of b12 from CHO
cells to primary bait. (B) Similar analysis was performed on samples of blood and
disaggregated colon tissue from an HIV controller for the comparison of responses in both
sites. HIV Env-specific antibodies were identified by screening with gp160-presenting MVs
(BaL strain, 50 μg/mL).
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Figure 5.
(A) Supernatants from cultures of HEK 293T cells expressing recombinant antibodies from
screens were collected and incubated over custom antigen microarrays, along with dilutions
of control antibodies (gp120-specific: b12, VRC01, b6, PG9, 2G12, 621κ and 479λ; gp41-
specific: 2F5 and 4E10; and HA-specific 4D20). Binding to spotted antigens and anti-Ig
capture species was detected with a fluorescently labeled goat anti-human antibody. Relative
affinities (Ag/Ig) of the different antibodies tested are presented as a heatmap. (B)
Neutralizing activity was tested on 4 antibodies against a panel of tier 1 and tier 2 HIV
strains.
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